A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment
收藏DataCite Commons2026-03-03 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006059/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
提供机构：
Vivli
创建时间：
2020-09-22
